Genenta Science announced a securities purchase agreement with institutional investors to purchase 4,285,715 American Depositary Shares at $3.50 each, totaling approximately $15.0 million. The offering, set to close on October 28, 2025, will fund working capital and general corporate purposes. Maxim Group LLC is the lead placement agent, and Rodman & Renshaw LLC is the co-placement agent. The securities are offered under a shelf registration statement and will be filed with the SEC. Genenta is a clinical-stage immuno-oncology company developing a therapy for solid tumor cancers, with a Phase 1 trial completed for Glioblastoma Multiforme patients.

Read more at GlobeNewswire: Genenta Announces Pricing of $15.0 Million Registered